2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

1466 Novel hematopoietic-specific model of aberrant APOBEC3A expression disrupts B cell genome, transcriptome, and development

Le'Mark Russell, Lynn White2, Danielle LaVigne3, Thi Tran4, Shuvro Nandi5, Ludmil Alexandrov6, Jeffrey Bednarski, MD, PhD7, Abby Green, MD8
1 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, Washington University in Saint Louis, Saint Louis, Missouri, United States
2 Washington University in Saint Louis, Saint Louis, Missouri, United States
3 Washington University in Saint Louis, Saint Louis, Missouri, United States
4 Washington University in Saint Louis, Saint Louis, Missouri, United States
5 University of California, San Diego, La Jolla, California, United States
6 University of California, San Diego, La Jolla, California, United States
7 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, Washington University in Saint Louis, Saint Louis, Missouri, United States
8 Washington University in Saint Louis, Saint Louis, Missouri, United States

B cell acute lymphoblastic leukemia (B-ALL) accounts for ~88% of pediatric leukemia cases. B-ALL results from the malignant transformation and proliferation of a specific subset of early B lymphocytes called precursor (pre-) B cells. Acquisition of DNA mutations is required for leukemia development, although the etiology of mutations in pediatric genomes is enigmatic. Several independent genome sequencing studies have identified two prominent single base substitution (SBS) patterns, or signatures, known as SBS2 and SBS13 in pediatric pre-B ALL. These mutational patterns are caused by activity of the APOBEC3A cytidine deaminase, an endogenous innate immune enzyme, which converts cytidine to uracil in DNA. Normally, APOBEC3A induces mutations in viral genomes leading to degradation, limited virion production, and virus restriction. However, aberrant APOBEC3A activity can act on host genome, particularly during DNA replication in proliferating cells, causing widespread mutations. Aberrant APOBEC3A has been implicated in the pathogenesis and maintenance of many different cancers. Despite correlative data demonstrating the mutagenic scars of APOBEC3A activity on B-ALL genomes, the role of APOBEC3A in pre-B leukemogenesis is unknown.

APOBEC3A is normally expressed in human hematopoietic cells, however there is no murine orthologue and to date no mouse model of APOBEC3A expression in the hematopoietic compartment exists. To investigate how APOBEC3A-mediated mutagenesis impacts normal hematopoiesis and contributes to pre-B cell leukemogenesis, we generated a novel mouse model with doxycycline-inducible, hematopoietic-specific expression of APOBEC3A (iA3A). A tetracycline responsive element followed by LOX-STOP-LOX cassette and APOBEC3A (Rosa26iA3A) was introduced into mice with VavCre and reverse tetracycline transactivator (RosartTA) transgenes (VavCre:RosartTA/iA3A). Cre recombinase is selectively expressed in hematopoietic cells resulting in inducible, hematopoietic-specific APOBEC3A expression. Treatment of VavCre:RosartTA/iA3A with doxycycline resulted in rapid induction of APOBEC3A expression in bone marrow hematopoietic stem and progenitor cells (HSPCs) and B cells. Subsequent withdrawal of doxycycline resulted in cessation of APOBEC3A expression. When expressed, APOBEC3A was active as demonstrated by in vitro deaminase assay. To confirm that APOBEC3A generates genomic mutations in vivo, we performed duplex sequencing on genomic DNA isolated from HSPCs and bone marrow B cells. SBS2 and SBS13 mutational signatures were substantially increased in frequency in both HSPCs and B cells from doxycycline-treated VavCre:RosartTA/iA3A mice compared to cells from control mice. To further assess the effect of APOBEC3A on pre-B cells specifically, we performed bulk RNA-sequencing on sorted pre-B cells from a VavCre:RosartTA/iA3A and control Rosa26rtTA/i3A mice treated with doxycycline chow for 1 week. Short-term expression of APOBEC3A disrupted pre-B cell transcriptional programs, including altered expression of genes necessary for early B cell development. To mimic the intermittent expression of APOBEC3A that occurs in human cells, we treated mice with doxycycline every other week and serially monitored peripheral blood populations. Long-term, intermittent APOBEC3A expression resulted in selective reduction of peripheral blood B cells with no changes in other white blood cell populations, hemoglobin, or platelets. Together these findings show that aberrant expression of APOBEC3A has deleterious effects on B cells, including generation of genomic mutations, alteration of gene expression, and reduction in cell numbers.

We have generated and characterized a novel model that enables investigation of APOBEC3A impact on development, genome integrity, and transformation of B cells in vivo. Ongoing studies will define how aberrant APOBEC3A activity generates mutations and alters B cells development to promote leukemogenesis. Together these studies will establish key insights into B-ALL pathogenesis.

Le'Mark Russell: No relevant conflicts of interest to declare.